Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nektar Therapeutics ( (NKTR) ) has issued an announcement.
On November 21, 2025, Nektar Therapeutics announced the departure of Mark A. Wilson as Chief Legal Officer, effective December 31, 2025, with no disagreements cited. Elizabeth Zhang, Vice President, Legal and Corporate Counsel, will assume his responsibilities, bringing experience from Cravath, Swaine & Moore LLP and Gibson, Dunn & Crutcher LLP.
The most recent analyst rating on (NKTR) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, high leverage, and negative profitability. However, the positive sentiment from the earnings call, highlighting strong cash reserves and promising clinical trial progress, provides some optimism. The technical analysis suggests potential upward momentum, but the high volatility and poor valuation metrics weigh down the score.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Average Trading Volume: 1,000,139
Technical Sentiment Signal: Hold
Current Market Cap: $1.23B
See more insights into NKTR stock on TipRanks’ Stock Analysis page.